Angela Toss, Assistant Professor in the Unit of Genetic Oncology of the Department of Medical and Surgical Sciences at the University of Modena and Reggio Emilia, shared a post on LinkedIn:
“Exploratory analysis of BRCA mutations in the MonarchE trial:
3.5% gBRCA1/2+ (lower than expected)
abema benefit in gBRCA, but not in sBRCA2 and RB1
caution for small sample size
Do CDK4/6i perform differently in gBRCA early BC patients compared to advanced disease?”
Source: Angela Toss/X
